Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S GOLD

Showing results (1151-1160 of 1,175) with videos related to

Pageof 118
Sort By:
Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Contemporary Clinical Trials|October 24, 2015
Lumbar Imaging With Reporting Of Epidemiology (LIRE)--Protocol for a pragmatic cluster randomized trialJeffrey G Jarvik, Bryan A Comstock, Kathryn T James, et al.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
JAMA Network Open|September 5, 2020
The Effect of Including Benchmark Prevalence Data of Common Imaging Findings in Spine Image Reports on Health Care Utilization Among Adults Undergoing Spine Imaging: A Stepped-Wedge Randomized Clinical TrialJeffrey G Jarvik, Eric N Meier, Kathryn T James, et al.
Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Ribosome-Associated Vesicles promote activity-dependent local translationEva Martin-Solana, Stephen D Carter, Eric K F Donahue, et al.
Gene & Protein in Disease|May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequencesKenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research|May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Science Advances|March 15, 2024
Redirecting raltitrexed from cancer cell thymidylate synthase to <i>Mycobacterium tuberculosis</i> phosphopantetheinyl transferaseAmrita Singh, Samantha Ottavi, Inna Krieger, et al.
Pageof 118

Showing results (1151-1160 of 1,175) with videos related to

Sort By:
Pageof 118
Current Pharmaceutical Biotechnology|April 18, 2025
A Comprehensive 4-Layered In Silico Pharmacogenomics Analysis of the Genetic Addiction Risk Severity (GARS) Test: Strong Genetic Evidence Supporting GARS as a Novel Personalized Pre-Addiction Assessment Tool in the Opioid Crisis EraAlireza Sharafshah, Kai-Uwe Lewandrowski, Igor Elman, et al.
Contemporary Clinical Trials|October 24, 2015
Lumbar Imaging With Reporting Of Epidemiology (LIRE)--Protocol for a pragmatic cluster randomized trialJeffrey G Jarvik, Bryan A Comstock, Kathryn T James, et al.
Current Neuropharmacology|January 27, 2025
In Silico Pharmacogenomic Assessment of Glucagon-like Peptide-1 (GLP1) Agonists and the Genetic Addiction Risk Score (GARS) Related Pathways: Implications for Suicide Ideation and Substance Use DisorderAlireza Sharafshah, Kai-Uwe Lewandrowski, Mark S Gold, et al.
JAMA Network Open|September 5, 2020
The Effect of Including Benchmark Prevalence Data of Common Imaging Findings in Spine Image Reports on Health Care Utilization Among Adults Undergoing Spine Imaging: A Stepped-Wedge Randomized Clinical TrialJeffrey G Jarvik, Eric N Meier, Kathryn T James, et al.
Acta Scientific Neurology|September 2, 2025
Dopaminergic Homeostatic Therapy (DHT<sup>™</sup>) as a Putative Anti-Addiction Seeking Intervention and Early Identification of Genetic Preaddiction with Genetic Addiction Risk Severity (GARS<sup>®</sup>) ScreeningKai-Uwe Lewandrowski, Abdalla Bowirrat, Albert Pinhasov, et al.
Biorxiv : the Preprint Server for Biology|June 19, 2024
Ribosome-Associated Vesicles promote activity-dependent local translationEva Martin-Solana, Stephen D Carter, Eric K F Donahue, et al.
Gene & Protein in Disease|May 20, 2024
Identification of stress-induced epigenetic methylation onto dopamine D2 gene and neurological and behavioral consequencesKenneth Blum, Abdalla Bowirrat, David Baron, et al.
British Journal of Healthcare and Medical Research|May 8, 2026
Reward Deficiency Syndrome (RDS): A Common Neurogenetic Trait/State of All Addictions: Is this the new DSM?Kenneth Blum, Kai Uwe Lewandrowski, Morgan P Lorio, et al.
Current Pharmaceutical Biotechnology|March 14, 2026
Pharmacogenomic-Based GWAS Meta-Analyses Coupled with Genetic and Epigenetic Liability Testing Connects Facial and Emotional Recognition Systems to Spectrum Disorders, Schizophrenia, Depression, and AnxietyKenneth Blum, Alexander P L Lewandrowski, Alireza Sharafshah, et al.
Science Advances|March 15, 2024
Redirecting raltitrexed from cancer cell thymidylate synthase to <i>Mycobacterium tuberculosis</i> phosphopantetheinyl transferaseAmrita Singh, Samantha Ottavi, Inna Krieger, et al.
Pageof 118